Mackay Shields LLC lowered its holdings in Tandem Diabetes Care Inc (NASDAQ:TNDM) by 6.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 75,800 shares of the medical device company’s stock after selling 5,200 shares during the quarter. Mackay Shields LLC owned 0.13% of Tandem Diabetes Care worth $4,471,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of TNDM. Nisa Investment Advisors LLC increased its stake in Tandem Diabetes Care by 53.3% in the second quarter. Nisa Investment Advisors LLC now owns 460 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 160 shares during the period. TRUE Private Wealth Advisors acquired a new position in Tandem Diabetes Care in the second quarter valued at about $33,000. First Quadrant L P CA acquired a new position in Tandem Diabetes Care in the third quarter valued at about $34,000. James Investment Research Inc. boosted its position in Tandem Diabetes Care by 15.9% in the second quarter. James Investment Research Inc. now owns 1,315 shares of the medical device company’s stock valued at $85,000 after buying an additional 180 shares in the last quarter. Finally, Stephens Inc. AR acquired a new position in Tandem Diabetes Care in the second quarter valued at about $113,000. 80.49% of the stock is currently owned by institutional investors and hedge funds.

Shares of TNDM stock traded down $1.85 during trading hours on Friday, reaching $57.36. 7,125,700 shares of the company were exchanged, compared to its average volume of 1,642,962. The stock’s fifty day moving average is $60.42 and its two-hundred day moving average is $63.80. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.46 and a quick ratio of 2.21. Tandem Diabetes Care Inc has a fifty-two week low of $26.40 and a fifty-two week high of $74.81. The company has a market cap of $3.42 billion, a price-to-earnings ratio of -22.49 and a beta of 0.16.

In other news, EVP Brian B. Hansen sold 6,969 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $70.00, for a total transaction of $487,830.00. Following the completion of the sale, the executive vice president now owns 9,960 shares of the company’s stock, valued at $697,200. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward L. Cahill sold 1,417 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $63.03, for a total transaction of $89,313.51. Following the sale, the director now directly owns 5,399 shares of the company’s stock, valued at approximately $340,298.97. The disclosure for this sale can be found here. Insiders have sold 458,221 shares of company stock valued at $32,039,235 in the last three months. 6.90% of the stock is owned by insiders.

A number of equities analysts have commented on TNDM shares. Robert W. Baird reduced their price target on shares of Tandem Diabetes Care from $81.00 to $71.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Oppenheimer boosted their price target on shares of Tandem Diabetes Care from $80.00 to $84.00 in a research report on Friday, August 2nd. Guggenheim started coverage on shares of Tandem Diabetes Care in a research report on Thursday, October 17th. They issued a “buy” rating and a $76.00 price target on the stock. BidaskClub lowered shares of Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Finally, ValuEngine upgraded shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $76.54.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Further Reading: What does the Dow Jones Industrial Average (DJIA) measure?

Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care Inc (NASDAQ:TNDM).

Institutional Ownership by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.